CN103314012A - 具有转录调控域和蛋白转导域的融合蛋白以及含有其的转录因子功能抑制剂 - Google Patents
具有转录调控域和蛋白转导域的融合蛋白以及含有其的转录因子功能抑制剂 Download PDFInfo
- Publication number
- CN103314012A CN103314012A CN201180050943XA CN201180050943A CN103314012A CN 103314012 A CN103314012 A CN 103314012A CN 201180050943X A CN201180050943X A CN 201180050943XA CN 201180050943 A CN201180050943 A CN 201180050943A CN 103314012 A CN103314012 A CN 103314012A
- Authority
- CN
- China
- Prior art keywords
- transcription factor
- domain
- fusion rotein
- factor
- cell
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 102000040945 Transcription factor Human genes 0.000 title claims abstract description 120
- 108091023040 Transcription factor Proteins 0.000 title claims abstract description 120
- 108090000623 proteins and genes Proteins 0.000 title claims abstract description 58
- 238000010361 transduction Methods 0.000 title claims abstract description 47
- 230000026683 transduction Effects 0.000 title claims abstract description 47
- 102000004169 proteins and genes Human genes 0.000 title claims abstract description 45
- 108020001507 fusion proteins Proteins 0.000 title abstract description 5
- 102000037865 fusion proteins Human genes 0.000 title abstract description 4
- 239000003112 inhibitor Substances 0.000 title abstract description 3
- 230000001105 regulatory effect Effects 0.000 claims abstract description 46
- 201000010099 disease Diseases 0.000 claims abstract description 43
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims abstract description 43
- 230000004927 fusion Effects 0.000 claims description 81
- 210000004027 cell Anatomy 0.000 claims description 72
- 230000002103 transcriptional effect Effects 0.000 claims description 48
- 230000002950 deficient Effects 0.000 claims description 30
- 108020004414 DNA Proteins 0.000 claims description 24
- 102000016978 Orphan receptors Human genes 0.000 claims description 18
- 108070000031 Orphan receptors Proteins 0.000 claims description 18
- SHGAZHPCJJPHSC-YCNIQYBTSA-N all-trans-retinoic acid Chemical compound OC(=O)\C=C(/C)\C=C\C=C(/C)\C=C\C1=C(C)CCCC1(C)C SHGAZHPCJJPHSC-YCNIQYBTSA-N 0.000 claims description 18
- 229930002330 retinoic acid Natural products 0.000 claims description 18
- 102100027581 Forkhead box protein P3 Human genes 0.000 claims description 16
- 101000861452 Homo sapiens Forkhead box protein P3 Proteins 0.000 claims description 16
- 230000005764 inhibitory process Effects 0.000 claims description 16
- 229960001727 tretinoin Drugs 0.000 claims description 16
- 108090000765 processed proteins & peptides Proteins 0.000 claims description 15
- 101001066288 Gallus gallus GATA-binding factor 3 Proteins 0.000 claims description 14
- 229940122954 Transcription factor inhibitor Drugs 0.000 claims description 14
- 239000008194 pharmaceutical composition Substances 0.000 claims description 14
- 208000006673 asthma Diseases 0.000 claims description 13
- 108010016731 PPAR gamma Proteins 0.000 claims description 12
- 238000000034 method Methods 0.000 claims description 12
- 108090000852 Forkhead Transcription Factors Proteins 0.000 claims description 11
- 102000004315 Forkhead Transcription Factors Human genes 0.000 claims description 11
- 208000023275 Autoimmune disease Diseases 0.000 claims description 10
- 101000819111 Homo sapiens Trans-acting T-cell-specific transcription factor GATA-3 Proteins 0.000 claims description 10
- 102100021386 Trans-acting T-cell-specific transcription factor GATA-3 Human genes 0.000 claims description 10
- 238000006471 dimerization reaction Methods 0.000 claims description 10
- 238000013518 transcription Methods 0.000 claims description 9
- 230000035897 transcription Effects 0.000 claims description 9
- 102100032742 Histone-lysine N-methyltransferase SETD2 Human genes 0.000 claims description 8
- 101000654725 Homo sapiens Histone-lysine N-methyltransferase SETD2 Proteins 0.000 claims description 8
- ROHFNLRQFUQHCH-YFKPBYRVSA-N L-leucine Chemical compound CC(C)C[C@H](N)C(O)=O ROHFNLRQFUQHCH-YFKPBYRVSA-N 0.000 claims description 8
- ROHFNLRQFUQHCH-UHFFFAOYSA-N Leucine Natural products CC(C)CC(N)C(O)=O ROHFNLRQFUQHCH-UHFFFAOYSA-N 0.000 claims description 8
- 108010091885 T-box transcription factor TBX21 Proteins 0.000 claims description 8
- 102100036840 T-box transcription factor TBX21 Human genes 0.000 claims description 8
- HCHKCACWOHOZIP-UHFFFAOYSA-N Zinc Chemical compound [Zn] HCHKCACWOHOZIP-UHFFFAOYSA-N 0.000 claims description 8
- 230000027455 binding Effects 0.000 claims description 8
- 108010018033 endothelial PAS domain-containing protein 1 Proteins 0.000 claims description 8
- 239000011701 zinc Substances 0.000 claims description 8
- 229910052725 zinc Inorganic materials 0.000 claims description 8
- 206010061218 Inflammation Diseases 0.000 claims description 7
- 230000006690 co-activation Effects 0.000 claims description 7
- 230000004054 inflammatory process Effects 0.000 claims description 7
- 101001059929 Caenorhabditis elegans Forkhead box protein O Proteins 0.000 claims description 6
- 102100036448 Endothelial PAS domain-containing protein 1 Human genes 0.000 claims description 6
- 108010057466 NF-kappa B Proteins 0.000 claims description 6
- 102000003945 NF-kappa B Human genes 0.000 claims description 6
- 206010028980 Neoplasm Diseases 0.000 claims description 6
- 101150114527 Nkx2-5 gene Proteins 0.000 claims description 6
- 102000000536 PPAR gamma Human genes 0.000 claims description 6
- 102000012132 Peroxisome proliferator-activated receptor gamma Human genes 0.000 claims description 6
- 102000005747 Transcription Factor RelA Human genes 0.000 claims description 6
- 108010031154 Transcription Factor RelA Proteins 0.000 claims description 6
- 101100460507 Xenopus laevis nkx-2.5 gene Proteins 0.000 claims description 6
- 239000012190 activator Substances 0.000 claims description 6
- 201000006417 multiple sclerosis Diseases 0.000 claims description 6
- 102000039446 nucleic acids Human genes 0.000 claims description 6
- 108020004707 nucleic acids Proteins 0.000 claims description 6
- 150000007523 nucleic acids Chemical class 0.000 claims description 6
- 101150019028 Antp gene Proteins 0.000 claims description 5
- 239000004475 Arginine Substances 0.000 claims description 5
- 101710149951 Protein Tat Proteins 0.000 claims description 5
- 101710192266 Tegument protein VP22 Proteins 0.000 claims description 5
- ODKSFYDXXFIFQN-UHFFFAOYSA-N arginine Natural products OC(=O)C(N)CCCNC(N)=N ODKSFYDXXFIFQN-UHFFFAOYSA-N 0.000 claims description 5
- 230000030648 nucleus localization Effects 0.000 claims description 5
- 230000008569 process Effects 0.000 claims description 5
- 230000006916 protein interaction Effects 0.000 claims description 5
- 108700031308 Antennapedia Homeodomain Proteins 0.000 claims description 4
- 230000004568 DNA-binding Effects 0.000 claims description 4
- 108010028501 Hypoxia-Inducible Factor 1 Proteins 0.000 claims description 4
- 102000016878 Hypoxia-Inducible Factor 1 Human genes 0.000 claims description 4
- 102100022875 Hypoxia-inducible factor 1-alpha Human genes 0.000 claims description 4
- 108050009527 Hypoxia-inducible factor-1 alpha Proteins 0.000 claims description 4
- 108010088535 Pep-1 peptide Proteins 0.000 claims description 4
- 201000011510 cancer Diseases 0.000 claims description 4
- 230000001086 cytosolic effect Effects 0.000 claims description 4
- 206010039073 rheumatoid arthritis Diseases 0.000 claims description 4
- 208000019553 vascular disease Diseases 0.000 claims description 4
- 208000022559 Inflammatory bowel disease Diseases 0.000 claims description 3
- 239000013604 expression vector Substances 0.000 claims description 3
- 206010020751 Hypersensitivity Diseases 0.000 claims description 2
- 208000012902 Nervous system disease Diseases 0.000 claims description 2
- 208000026935 allergic disease Diseases 0.000 claims description 2
- 230000007815 allergy Effects 0.000 claims description 2
- 206010012601 diabetes mellitus Diseases 0.000 claims description 2
- 210000001035 gastrointestinal tract Anatomy 0.000 claims description 2
- 208000019622 heart disease Diseases 0.000 claims description 2
- 238000004519 manufacturing process Methods 0.000 abstract 1
- 208000028911 Temporomandibular Joint disease Diseases 0.000 description 153
- 208000008963 Transient myeloproliferative syndrome Diseases 0.000 description 153
- 230000000694 effects Effects 0.000 description 42
- 235000018102 proteins Nutrition 0.000 description 34
- 230000028327 secretion Effects 0.000 description 32
- 210000000068 Th17 cell Anatomy 0.000 description 30
- 208000033068 episodic angioedema with eosinophilia Diseases 0.000 description 30
- 108050003558 Interleukin-17 Proteins 0.000 description 25
- 102000013691 Interleukin-17 Human genes 0.000 description 24
- 210000001744 T-lymphocyte Anatomy 0.000 description 22
- 210000000447 Th1 cell Anatomy 0.000 description 16
- 210000002501 natural regulatory T cell Anatomy 0.000 description 16
- 238000010171 animal model Methods 0.000 description 15
- 210000002602 induced regulatory T cell Anatomy 0.000 description 14
- 102000004127 Cytokines Human genes 0.000 description 13
- 108090000695 Cytokines Proteins 0.000 description 13
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 13
- 201000009961 allergic asthma Diseases 0.000 description 11
- -1 T-frame 21) Proteins 0.000 description 10
- 210000004241 Th2 cell Anatomy 0.000 description 10
- 230000008859 change Effects 0.000 description 10
- 239000003795 chemical substances by application Substances 0.000 description 10
- 210000000952 spleen Anatomy 0.000 description 10
- 206010033799 Paralysis Diseases 0.000 description 9
- 238000002360 preparation method Methods 0.000 description 9
- 102000004388 Interleukin-4 Human genes 0.000 description 7
- 108090000978 Interleukin-4 Proteins 0.000 description 7
- 150000001413 amino acids Chemical group 0.000 description 7
- 238000004458 analytical method Methods 0.000 description 7
- 238000002474 experimental method Methods 0.000 description 7
- 230000008595 infiltration Effects 0.000 description 7
- 238000001764 infiltration Methods 0.000 description 7
- 239000000203 mixture Substances 0.000 description 7
- 238000011740 C57BL/6 mouse Methods 0.000 description 6
- 238000002965 ELISA Methods 0.000 description 6
- 102000000588 Interleukin-2 Human genes 0.000 description 6
- 108010002350 Interleukin-2 Proteins 0.000 description 6
- 108060001084 Luciferase Proteins 0.000 description 6
- 239000005089 Luciferase Substances 0.000 description 6
- DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 description 6
- 238000004043 dyeing Methods 0.000 description 6
- 210000004969 inflammatory cell Anatomy 0.000 description 6
- 230000003834 intracellular effect Effects 0.000 description 6
- 210000004072 lung Anatomy 0.000 description 6
- 239000011780 sodium chloride Substances 0.000 description 6
- 210000004988 splenocyte Anatomy 0.000 description 6
- 235000001014 amino acid Nutrition 0.000 description 5
- 239000000427 antigen Substances 0.000 description 5
- 238000013459 approach Methods 0.000 description 5
- 230000028993 immune response Effects 0.000 description 5
- 239000007788 liquid Substances 0.000 description 5
- 210000001519 tissue Anatomy 0.000 description 5
- 239000003981 vehicle Substances 0.000 description 5
- VTYYLEPIZMXCLO-UHFFFAOYSA-L Calcium carbonate Chemical compound [Ca+2].[O-]C([O-])=O VTYYLEPIZMXCLO-UHFFFAOYSA-L 0.000 description 4
- 208000016192 Demyelinating disease Diseases 0.000 description 4
- 206010012305 Demyelination Diseases 0.000 description 4
- LYCAIKOWRPUZTN-UHFFFAOYSA-N Ethylene glycol Chemical compound OCCO LYCAIKOWRPUZTN-UHFFFAOYSA-N 0.000 description 4
- 108700039691 Genetic Promoter Regions Proteins 0.000 description 4
- WZUVPPKBWHMQCE-UHFFFAOYSA-N Haematoxylin Chemical compound C12=CC(O)=C(O)C=C2CC2(O)C1C1=CC=C(O)C(O)=C1OC2 WZUVPPKBWHMQCE-UHFFFAOYSA-N 0.000 description 4
- 102100037850 Interferon gamma Human genes 0.000 description 4
- 108010074328 Interferon-gamma Proteins 0.000 description 4
- 102100023302 Myelin-oligodendrocyte glycoprotein Human genes 0.000 description 4
- IQFYYKKMVGJFEH-XLPZGREQSA-N Thymidine Chemical compound O=C1NC(=O)C(C)=CN1[C@@H]1O[C@H](CO)[C@@H](O)C1 IQFYYKKMVGJFEH-XLPZGREQSA-N 0.000 description 4
- 108091007433 antigens Proteins 0.000 description 4
- 102000036639 antigens Human genes 0.000 description 4
- 210000004369 blood Anatomy 0.000 description 4
- 239000008280 blood Substances 0.000 description 4
- 238000010231 histologic analysis Methods 0.000 description 4
- 150000002460 imidazoles Chemical class 0.000 description 4
- 230000002757 inflammatory effect Effects 0.000 description 4
- 238000002826 magnetic-activated cell sorting Methods 0.000 description 4
- 210000000278 spinal cord Anatomy 0.000 description 4
- 208000024891 symptom Diseases 0.000 description 4
- 238000012360 testing method Methods 0.000 description 4
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 3
- 101001013648 Homo sapiens Methionine synthase Proteins 0.000 description 3
- 108010002616 Interleukin-5 Proteins 0.000 description 3
- 102000000743 Interleukin-5 Human genes 0.000 description 3
- 108091028043 Nucleic acid sequence Proteins 0.000 description 3
- 125000000539 amino acid group Chemical group 0.000 description 3
- 210000003169 central nervous system Anatomy 0.000 description 3
- 238000013016 damping Methods 0.000 description 3
- 210000003162 effector t lymphocyte Anatomy 0.000 description 3
- 239000012530 fluid Substances 0.000 description 3
- 238000001943 fluorescence-activated cell sorting Methods 0.000 description 3
- 230000036737 immune function Effects 0.000 description 3
- 230000006698 induction Effects 0.000 description 3
- 230000001939 inductive effect Effects 0.000 description 3
- 230000002401 inhibitory effect Effects 0.000 description 3
- 239000007924 injection Substances 0.000 description 3
- 238000002347 injection Methods 0.000 description 3
- 238000007912 intraperitoneal administration Methods 0.000 description 3
- 210000001331 nose Anatomy 0.000 description 3
- 230000002265 prevention Effects 0.000 description 3
- 230000002829 reductive effect Effects 0.000 description 3
- 238000011160 research Methods 0.000 description 3
- 230000000452 restraining effect Effects 0.000 description 3
- 239000007787 solid Substances 0.000 description 3
- 208000032116 Autoimmune Experimental Encephalomyelitis Diseases 0.000 description 2
- DWRXFEITVBNRMK-UHFFFAOYSA-N Beta-D-1-Arabinofuranosylthymine Natural products O=C1NC(=O)C(C)=CN1C1C(O)C(O)C(CO)O1 DWRXFEITVBNRMK-UHFFFAOYSA-N 0.000 description 2
- 208000031648 Body Weight Changes Diseases 0.000 description 2
- 206010062016 Immunosuppression Diseases 0.000 description 2
- 102000003816 Interleukin-13 Human genes 0.000 description 2
- 108090000176 Interleukin-13 Proteins 0.000 description 2
- ODKSFYDXXFIFQN-BYPYZUCNSA-P L-argininium(2+) Chemical compound NC(=[NH2+])NCCC[C@H]([NH3+])C(O)=O ODKSFYDXXFIFQN-BYPYZUCNSA-P 0.000 description 2
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 2
- LUWJPTVQOMUZLW-UHFFFAOYSA-N Luxol fast blue MBS Chemical compound [Cu++].Cc1ccccc1N\C(N)=N\c1ccccc1C.Cc1ccccc1N\C(N)=N\c1ccccc1C.OS(=O)(=O)c1cccc2c3nc(nc4nc([n-]c5[n-]c(nc6nc(n3)c3ccccc63)c3c(cccc53)S(O)(=O)=O)c3ccccc43)c12 LUWJPTVQOMUZLW-UHFFFAOYSA-N 0.000 description 2
- 229920003171 Poly (ethylene oxide) Polymers 0.000 description 2
- 229930006000 Sucrose Natural products 0.000 description 2
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 2
- 230000006052 T cell proliferation Effects 0.000 description 2
- 210000000662 T-lymphocyte subset Anatomy 0.000 description 2
- 230000003213 activating effect Effects 0.000 description 2
- 239000003125 aqueous solvent Substances 0.000 description 2
- IQFYYKKMVGJFEH-UHFFFAOYSA-N beta-L-thymidine Natural products O=C1NC(=O)C(C)=CN1C1OC(CO)C(O)C1 IQFYYKKMVGJFEH-UHFFFAOYSA-N 0.000 description 2
- 238000010876 biochemical test Methods 0.000 description 2
- 230000008512 biological response Effects 0.000 description 2
- 230000008499 blood brain barrier function Effects 0.000 description 2
- 210000001218 blood-brain barrier Anatomy 0.000 description 2
- 230000037396 body weight Effects 0.000 description 2
- 230000004579 body weight change Effects 0.000 description 2
- 229910000019 calcium carbonate Inorganic materials 0.000 description 2
- 239000002775 capsule Substances 0.000 description 2
- 238000004113 cell culture Methods 0.000 description 2
- 230000006957 competitive inhibition Effects 0.000 description 2
- 230000002596 correlated effect Effects 0.000 description 2
- 239000012228 culture supernatant Substances 0.000 description 2
- 230000004069 differentiation Effects 0.000 description 2
- 239000012636 effector Substances 0.000 description 2
- 239000012149 elution buffer Substances 0.000 description 2
- 239000000839 emulsion Substances 0.000 description 2
- 238000005516 engineering process Methods 0.000 description 2
- YQGOJNYOYNNSMM-UHFFFAOYSA-N eosin Chemical compound [Na+].OC(=O)C1=CC=CC=C1C1=C2C=C(Br)C(=O)C(Br)=C2OC2=C(Br)C(O)=C(Br)C=C21 YQGOJNYOYNNSMM-UHFFFAOYSA-N 0.000 description 2
- 208000012997 experimental autoimmune encephalomyelitis Diseases 0.000 description 2
- 230000009454 functional inhibition Effects 0.000 description 2
- 239000008187 granular material Substances 0.000 description 2
- 235000014304 histidine Nutrition 0.000 description 2
- WGCNASOHLSPBMP-UHFFFAOYSA-N hydroxyacetaldehyde Natural products OCC=O WGCNASOHLSPBMP-UHFFFAOYSA-N 0.000 description 2
- 238000011532 immunohistochemical staining Methods 0.000 description 2
- 230000001506 immunosuppresive effect Effects 0.000 description 2
- 238000010212 intracellular staining Methods 0.000 description 2
- PGHMRUGBZOYCAA-ADZNBVRBSA-N ionomycin Chemical compound O1[C@H](C[C@H](O)[C@H](C)[C@H](O)[C@H](C)/C=C/C[C@@H](C)C[C@@H](C)C(/O)=C/C(=O)[C@@H](C)C[C@@H](C)C[C@@H](CCC(O)=O)C)CC[C@@]1(C)[C@@H]1O[C@](C)([C@@H](C)O)CC1 PGHMRUGBZOYCAA-ADZNBVRBSA-N 0.000 description 2
- PGHMRUGBZOYCAA-UHFFFAOYSA-N ionomycin Natural products O1C(CC(O)C(C)C(O)C(C)C=CCC(C)CC(C)C(O)=CC(=O)C(C)CC(C)CC(CCC(O)=O)C)CCC1(C)C1OC(C)(C(C)O)CC1 PGHMRUGBZOYCAA-UHFFFAOYSA-N 0.000 description 2
- BPHPUYQFMNQIOC-NXRLNHOXSA-N isopropyl beta-D-thiogalactopyranoside Chemical compound CC(C)S[C@@H]1O[C@H](CO)[C@H](O)[C@H](O)[C@H]1O BPHPUYQFMNQIOC-NXRLNHOXSA-N 0.000 description 2
- 239000008101 lactose Substances 0.000 description 2
- 108020001756 ligand binding domains Proteins 0.000 description 2
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 2
- 238000007898 magnetic cell sorting Methods 0.000 description 2
- 206010025482 malaise Diseases 0.000 description 2
- 239000003607 modifier Substances 0.000 description 2
- 230000035772 mutation Effects 0.000 description 2
- 239000012188 paraffin wax Substances 0.000 description 2
- 244000052769 pathogen Species 0.000 description 2
- 230000001717 pathogenic effect Effects 0.000 description 2
- 229920000136 polysorbate Polymers 0.000 description 2
- 230000001737 promoting effect Effects 0.000 description 2
- 238000002415 sodium dodecyl sulfate polyacrylamide gel electrophoresis Methods 0.000 description 2
- 210000004989 spleen cell Anatomy 0.000 description 2
- 238000010186 staining Methods 0.000 description 2
- 239000005720 sucrose Substances 0.000 description 2
- 239000000829 suppository Substances 0.000 description 2
- 239000006188 syrup Substances 0.000 description 2
- 235000020357 syrup Nutrition 0.000 description 2
- 239000003826 tablet Substances 0.000 description 2
- 229940104230 thymidine Drugs 0.000 description 2
- 239000003053 toxin Substances 0.000 description 2
- 231100000765 toxin Toxicity 0.000 description 2
- 108700012359 toxins Proteins 0.000 description 2
- 238000001890 transfection Methods 0.000 description 2
- 238000001262 western blot Methods 0.000 description 2
- 239000000080 wetting agent Substances 0.000 description 2
- FWBHETKCLVMNFS-UHFFFAOYSA-N 4',6-Diamino-2-phenylindol Chemical compound C1=CC(C(=N)N)=CC=C1C1=CC2=CC=C(C(N)=N)C=C2N1 FWBHETKCLVMNFS-UHFFFAOYSA-N 0.000 description 1
- 238000011725 BALB/c mouse Methods 0.000 description 1
- LVGKNOAMLMIIKO-UHFFFAOYSA-N Elaidinsaeure-aethylester Natural products CCCCCCCCC=CCCCCCCCC(=O)OCC LVGKNOAMLMIIKO-UHFFFAOYSA-N 0.000 description 1
- 239000004606 Fillers/Extenders Substances 0.000 description 1
- WSFSSNUMVMOOMR-UHFFFAOYSA-N Formaldehyde Chemical compound O=C WSFSSNUMVMOOMR-UHFFFAOYSA-N 0.000 description 1
- 230000005526 G1 to G0 transition Effects 0.000 description 1
- 108010010803 Gelatin Proteins 0.000 description 1
- 102100036646 Glutamyl-tRNA(Gln) amidotransferase subunit A, mitochondrial Human genes 0.000 description 1
- 101001072655 Homo sapiens Glutamyl-tRNA(Gln) amidotransferase subunit A, mitochondrial Proteins 0.000 description 1
- 101000914514 Homo sapiens T-cell-specific surface glycoprotein CD28 Proteins 0.000 description 1
- 108090001005 Interleukin-6 Proteins 0.000 description 1
- 241001465754 Metazoa Species 0.000 description 1
- 206010027926 Monoplegia Diseases 0.000 description 1
- 108010083674 Myelin Proteins Proteins 0.000 description 1
- 102000006386 Myelin Proteins Human genes 0.000 description 1
- 108700020796 Oncogene Proteins 0.000 description 1
- 108010062618 Oncogene Proteins v-rel Proteins 0.000 description 1
- 239000012124 Opti-MEM Substances 0.000 description 1
- 201000005702 Pertussis Diseases 0.000 description 1
- 108020004511 Recombinant DNA Proteins 0.000 description 1
- 241000712909 Reticuloendotheliosis virus Species 0.000 description 1
- CWHJIJJSDGEHNS-MYLFLSLOSA-N Senegenin Chemical compound C1[C@H](O)[C@H](O)[C@@](C)(C(O)=O)[C@@H]2CC[C@@]3(C)C(CC[C@]4(CCC(C[C@H]44)(C)C)C(O)=O)=C4[C@@H](CCl)C[C@@H]3[C@]21C CWHJIJJSDGEHNS-MYLFLSLOSA-N 0.000 description 1
- 229920002472 Starch Polymers 0.000 description 1
- 230000006044 T cell activation Effects 0.000 description 1
- 102100027213 T-cell-specific surface glycoprotein CD28 Human genes 0.000 description 1
- 235000009470 Theobroma cacao Nutrition 0.000 description 1
- 102000046299 Transforming Growth Factor beta1 Human genes 0.000 description 1
- 101800002279 Transforming growth factor beta-1 Proteins 0.000 description 1
- 230000002159 abnormal effect Effects 0.000 description 1
- 239000002253 acid Substances 0.000 description 1
- 230000009471 action Effects 0.000 description 1
- 239000013543 active substance Substances 0.000 description 1
- 230000001154 acute effect Effects 0.000 description 1
- 230000007059 acute toxicity Effects 0.000 description 1
- 231100000403 acute toxicity Toxicity 0.000 description 1
- 239000000443 aerosol Substances 0.000 description 1
- WNROFYMDJYEPJX-UHFFFAOYSA-K aluminium hydroxide Chemical compound [OH-].[OH-].[OH-].[Al+3] WNROFYMDJYEPJX-UHFFFAOYSA-K 0.000 description 1
- 229910021502 aluminium hydroxide Inorganic materials 0.000 description 1
- 230000007503 antigenic stimulation Effects 0.000 description 1
- 239000007864 aqueous solution Substances 0.000 description 1
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 1
- 238000011888 autopsy Methods 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 239000012148 binding buffer Substances 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 210000004556 brain Anatomy 0.000 description 1
- 206010006451 bronchitis Diseases 0.000 description 1
- 239000007853 buffer solution Substances 0.000 description 1
- 210000004899 c-terminal region Anatomy 0.000 description 1
- 244000240602 cacao Species 0.000 description 1
- 239000013592 cell lysate Substances 0.000 description 1
- 238000006243 chemical reaction Methods 0.000 description 1
- 239000003153 chemical reaction reagent Substances 0.000 description 1
- 230000001684 chronic effect Effects 0.000 description 1
- 238000004140 cleaning Methods 0.000 description 1
- 230000003081 coactivator Effects 0.000 description 1
- 150000001875 compounds Chemical class 0.000 description 1
- 239000003636 conditioned culture medium Substances 0.000 description 1
- 235000009508 confectionery Nutrition 0.000 description 1
- 238000012790 confirmation Methods 0.000 description 1
- 230000001276 controlling effect Effects 0.000 description 1
- NKLPQNGYXWVELD-UHFFFAOYSA-M coomassie brilliant blue Chemical compound [Na+].C1=CC(OCC)=CC=C1NC1=CC=C(C(=C2C=CC(C=C2)=[N+](CC)CC=2C=C(C=CC=2)S([O-])(=O)=O)C=2C=CC(=CC=2)N(CC)CC=2C=C(C=CC=2)S([O-])(=O)=O)C=C1 NKLPQNGYXWVELD-UHFFFAOYSA-M 0.000 description 1
- 238000012258 culturing Methods 0.000 description 1
- 230000003013 cytotoxicity Effects 0.000 description 1
- 231100000135 cytotoxicity Toxicity 0.000 description 1
- 230000034994 death Effects 0.000 description 1
- 210000004443 dendritic cell Anatomy 0.000 description 1
- 238000001514 detection method Methods 0.000 description 1
- FPAFDBFIGPHWGO-UHFFFAOYSA-N dioxosilane;oxomagnesium;hydrate Chemical compound O.[Mg]=O.[Mg]=O.[Mg]=O.O=[Si]=O.O=[Si]=O.O=[Si]=O.O=[Si]=O FPAFDBFIGPHWGO-UHFFFAOYSA-N 0.000 description 1
- 230000006806 disease prevention Effects 0.000 description 1
- 150000002148 esters Chemical class 0.000 description 1
- LVGKNOAMLMIIKO-QXMHVHEDSA-N ethyl oleate Chemical compound CCCCCCCC\C=C/CCCCCCCC(=O)OCC LVGKNOAMLMIIKO-QXMHVHEDSA-N 0.000 description 1
- 229940093471 ethyl oleate Drugs 0.000 description 1
- 230000003203 everyday effect Effects 0.000 description 1
- 238000000605 extraction Methods 0.000 description 1
- 210000001508 eye Anatomy 0.000 description 1
- 239000000945 filler Substances 0.000 description 1
- 235000003599 food sweetener Nutrition 0.000 description 1
- 239000008098 formaldehyde solution Substances 0.000 description 1
- 238000009472 formulation Methods 0.000 description 1
- 230000008014 freezing Effects 0.000 description 1
- 238000007710 freezing Methods 0.000 description 1
- 229920000159 gelatin Polymers 0.000 description 1
- 239000008273 gelatin Substances 0.000 description 1
- 235000019322 gelatine Nutrition 0.000 description 1
- 235000011852 gelatine desserts Nutrition 0.000 description 1
- 235000011187 glycerol Nutrition 0.000 description 1
- 239000008359 glycogelatin Substances 0.000 description 1
- HNDVDQJCIGZPNO-UHFFFAOYSA-N histidine Natural products OC(=O)C(N)CC1=CN=CN1 HNDVDQJCIGZPNO-UHFFFAOYSA-N 0.000 description 1
- 150000002411 histidines Chemical class 0.000 description 1
- XMBWDFGMSWQBCA-UHFFFAOYSA-N hydrogen iodide Chemical compound I XMBWDFGMSWQBCA-UHFFFAOYSA-N 0.000 description 1
- 230000008629 immune suppression Effects 0.000 description 1
- 238000012151 immunohistochemical method Methods 0.000 description 1
- 238000000338 in vitro Methods 0.000 description 1
- 238000001727 in vivo Methods 0.000 description 1
- 230000003993 interaction Effects 0.000 description 1
- 230000000968 intestinal effect Effects 0.000 description 1
- 239000007928 intraperitoneal injection Substances 0.000 description 1
- 208000002551 irritable bowel syndrome Diseases 0.000 description 1
- 150000002632 lipids Chemical class 0.000 description 1
- 238000001638 lipofection Methods 0.000 description 1
- 239000002502 liposome Substances 0.000 description 1
- 239000000314 lubricant Substances 0.000 description 1
- 239000012139 lysis buffer Substances 0.000 description 1
- 235000019359 magnesium stearate Nutrition 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 230000010534 mechanism of action Effects 0.000 description 1
- 230000001404 mediated effect Effects 0.000 description 1
- 231100000668 minimum lethal dose Toxicity 0.000 description 1
- 210000005012 myelin Anatomy 0.000 description 1
- 210000003928 nasal cavity Anatomy 0.000 description 1
- 210000002569 neuron Anatomy 0.000 description 1
- 229940100688 oral solution Drugs 0.000 description 1
- 210000000056 organ Anatomy 0.000 description 1
- 230000008520 organization Effects 0.000 description 1
- 229910052760 oxygen Inorganic materials 0.000 description 1
- 239000001301 oxygen Substances 0.000 description 1
- 239000003182 parenteral nutrition solution Substances 0.000 description 1
- 210000002824 peroxisome Anatomy 0.000 description 1
- 239000000546 pharmaceutical excipient Substances 0.000 description 1
- 239000006187 pill Substances 0.000 description 1
- 239000013612 plasmid Substances 0.000 description 1
- 238000012545 processing Methods 0.000 description 1
- 230000035755 proliferation Effects 0.000 description 1
- 238000000746 purification Methods 0.000 description 1
- 102000005962 receptors Human genes 0.000 description 1
- 108020003175 receptors Proteins 0.000 description 1
- 230000008521 reorganization Effects 0.000 description 1
- 238000005316 response function Methods 0.000 description 1
- 210000003491 skin Anatomy 0.000 description 1
- 239000002002 slurry Substances 0.000 description 1
- 239000007921 spray Substances 0.000 description 1
- 239000008107 starch Substances 0.000 description 1
- 235000019698 starch Nutrition 0.000 description 1
- 238000007920 subcutaneous administration Methods 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 239000002511 suppository base Substances 0.000 description 1
- 239000003765 sweetening agent Substances 0.000 description 1
- 239000009871 tenuigenin Substances 0.000 description 1
- 230000036962 time dependent Effects 0.000 description 1
- 230000000699 topical effect Effects 0.000 description 1
- 231100000331 toxic Toxicity 0.000 description 1
- 230000002588 toxic effect Effects 0.000 description 1
- 231100000419 toxicity Toxicity 0.000 description 1
- 230000001988 toxicity Effects 0.000 description 1
- 108091006106 transcriptional activators Proteins 0.000 description 1
- 239000012096 transfection reagent Substances 0.000 description 1
- 210000001364 upper extremity Anatomy 0.000 description 1
- 235000013311 vegetables Nutrition 0.000 description 1
- 238000011179 visual inspection Methods 0.000 description 1
- 238000005406 washing Methods 0.000 description 1
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 1
Images
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K19/00—Hybrid peptides, i.e. peptides covalently bound to nucleic acids, or non-covalently bound protein-protein complexes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
- C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
- C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
- C07K14/4702—Regulators; Modulating activity
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
- C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
- C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
- C07K14/4702—Regulators; Modulating activity
- C07K14/4703—Inhibitors; Suppressors
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
- C12N15/62—DNA sequences coding for fusion proteins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
- C07K2319/10—Fusion polypeptide containing a localisation/targetting motif containing a tag for extracellular membrane crossing, e.g. TAT or VP22
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/70—Fusion polypeptide containing domain for protein-protein interaction
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/70—Fusion polypeptide containing domain for protein-protein interaction
- C07K2319/73—Fusion polypeptide containing domain for protein-protein interaction containing coiled-coiled motif (leucine zippers)
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/80—Fusion polypeptide containing a DNA binding domain, e.g. Lacl or Tet-repressor
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/80—Fusion polypeptide containing a DNA binding domain, e.g. Lacl or Tet-repressor
- C07K2319/81—Fusion polypeptide containing a DNA binding domain, e.g. Lacl or Tet-repressor containing a Zn-finger domain for DNA binding
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Genetics & Genomics (AREA)
- Engineering & Computer Science (AREA)
- Biochemistry (AREA)
- Molecular Biology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Biophysics (AREA)
- Zoology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Biomedical Technology (AREA)
- Toxicology (AREA)
- Gastroenterology & Hepatology (AREA)
- Pulmonology (AREA)
- Wood Science & Technology (AREA)
- General Engineering & Computer Science (AREA)
- Biotechnology (AREA)
- Rheumatology (AREA)
- Immunology (AREA)
- Microbiology (AREA)
- Physics & Mathematics (AREA)
- Plant Pathology (AREA)
- Neurology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Physical Education & Sports Medicine (AREA)
- Neurosurgery (AREA)
- Pain & Pain Management (AREA)
- Peptides Or Proteins (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Abstract
Description
Claims (40)
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201810559215.5A CN108822215B (zh) | 2010-08-20 | 2011-08-19 | 具有转录调控域和蛋白转导域的融合蛋白以及含有其的转录因子功能抑制剂 |
Applications Claiming Priority (5)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
KR1020100080864A KR101525856B1 (ko) | 2010-08-20 | 2010-08-20 | 전사인자의 dna 결합 도메인 및 단백질 운반 도메인을 포함하는 융합단백질을 가지는 전사인자 억제제 및 이의 제조방법 |
KR10-2010-0080864 | 2010-08-20 | ||
KR10-2010-0126455 | 2010-12-10 | ||
KR1020100126455A KR101557343B1 (ko) | 2010-12-10 | 2010-12-10 | 전사인자 gata-3의 dna 결합 도메인과 단백질 운반 도메인을 융합한 단백질을 이용한 알러지성 천식 치료용 약학 조성물 및 이를 이용한 치료방법 |
PCT/KR2011/006158 WO2012023838A2 (ko) | 2010-08-20 | 2011-08-19 | 전사인자의 전사활성 조절도메인 및 단백질 운반 도메인을 가지는 융합단백질 및 이를 포함하는 전사인자 기능억제제 |
Related Child Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN201810559215.5A Division CN108822215B (zh) | 2010-08-20 | 2011-08-19 | 具有转录调控域和蛋白转导域的融合蛋白以及含有其的转录因子功能抑制剂 |
Publications (2)
Publication Number | Publication Date |
---|---|
CN103314012A true CN103314012A (zh) | 2013-09-18 |
CN103314012B CN103314012B (zh) | 2018-07-10 |
Family
ID=45605587
Family Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN201810559215.5A Active CN108822215B (zh) | 2010-08-20 | 2011-08-19 | 具有转录调控域和蛋白转导域的融合蛋白以及含有其的转录因子功能抑制剂 |
CN201180050943.XA Active CN103314012B (zh) | 2010-08-20 | 2011-08-19 | 具有转录调控域和蛋白转导域的融合蛋白以及含有其的转录因子功能抑制剂 |
Family Applications Before (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN201810559215.5A Active CN108822215B (zh) | 2010-08-20 | 2011-08-19 | 具有转录调控域和蛋白转导域的融合蛋白以及含有其的转录因子功能抑制剂 |
Country Status (5)
Country | Link |
---|---|
US (1) | US9546221B2 (zh) |
EP (3) | EP3875474A1 (zh) |
JP (1) | JP5911869B2 (zh) |
CN (2) | CN108822215B (zh) |
WO (1) | WO2012023838A2 (zh) |
Cited By (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN104530241A (zh) * | 2014-12-15 | 2015-04-22 | 武汉市畜牧兽医科学研究所 | 一种表达穿膜肽融合蛋白的基因工程菌及应用 |
CN114958921A (zh) * | 2022-04-18 | 2022-08-30 | 复旦大学附属中山医院 | 一种提高调节型t细胞稳定性和功能的方法 |
Families Citing this family (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US8987416B2 (en) * | 2013-08-08 | 2015-03-24 | David A. Paslin | Viral fusion protein treatment for CCR8 mediated diseases |
KR101889140B1 (ko) * | 2015-10-12 | 2018-08-17 | 연세대학교 산학협력단 | p65의 전사 조절 도메인과 단백질 운반 도메인을 포함하는 신규 융합 단백질 및 이의 용도 |
JP7051687B2 (ja) * | 2016-01-06 | 2022-04-11 | グッド ティー セルズ、 インコーポレイテッド | P65の転写調節ドメインと蛋白質運搬ドメインとを含む新規融合蛋白質およびその用途 |
DE102017200007A1 (de) | 2017-01-02 | 2018-07-05 | Schott Ag | Spritze mit unterschiedlichen Materialien |
Citations (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN101511873A (zh) * | 2006-08-31 | 2009-08-19 | 为人技术株式会社 | 用于抑制神经递质分泌的融合多肽和递送该融合多肽的方法 |
Family Cites Families (18)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US8048672B2 (en) * | 1999-06-02 | 2011-11-01 | President And Fellows Of Harvard College | T-bet compositions and methods of use thereof |
CA2317786A1 (en) * | 2000-09-06 | 2002-03-06 | Advantage Interactive Corporation | A system and method for providing an automated interview |
US7212985B2 (en) * | 2000-10-10 | 2007-05-01 | Intragroup, Inc. | Automated system and method for managing a process for the shopping and selection of human entities |
US7778938B2 (en) * | 2001-06-05 | 2010-08-17 | Accuhire.Com Corporation | System and method for screening of job applicants |
KR100591936B1 (ko) * | 2002-11-12 | 2006-06-22 | 포휴먼텍(주) | 세포내 dna/rna 전달 방법, 및 이것의 기초 및임상학적 응용 |
US20040186743A1 (en) * | 2003-01-27 | 2004-09-23 | Angel Cordero | System, method and software for individuals to experience an interview simulation and to develop career and interview skills |
US20050033633A1 (en) * | 2003-08-04 | 2005-02-10 | Lapasta Douglas G. | System and method for evaluating job candidates |
US20050055231A1 (en) * | 2003-09-08 | 2005-03-10 | Lee Geoffrey C. | Candidate-initiated background check and verification |
US20050118655A1 (en) * | 2003-11-17 | 2005-06-02 | University Of Iowa Research Foundation | Use of parasitic biological agents for diseases prevention and control |
US20060224404A1 (en) * | 2005-04-05 | 2006-10-05 | Carl Keusseyan | Web-based system and method for screening job candidates |
US20070088601A1 (en) * | 2005-04-09 | 2007-04-19 | Hirevue | On-line interview processing |
US20070178113A1 (en) * | 2005-11-22 | 2007-08-02 | Backstrom B T | Superantigen conjugate |
WO2008002107A1 (en) * | 2006-06-30 | 2008-01-03 | Forhumantech Co., Ltd. | Pharmaceutical composition for treating autoimmune, allergic and inflammatory diseases and delivery method thereof |
CN101117635B (zh) * | 2006-07-31 | 2013-07-31 | 中国人民解放军军事医学科学院毒物药物研究所 | Ptd、hif的odd与肿瘤抑制基因的融合表达及其应用 |
WO2008086484A2 (en) * | 2007-01-10 | 2008-07-17 | The Cleveland Clinic Foundation | Compositions and methods for treating cardiovascular disease |
US8454955B2 (en) * | 2007-11-28 | 2013-06-04 | Riken | Methods for treating allergic airway inflammation, airway hypersensitivity, and eosinophilia |
JP5572796B2 (ja) * | 2008-02-13 | 2014-08-20 | 国立大学法人 千葉大学 | ゲラニルゲラニル化阻害による制御性t細胞の分化誘導およびその治療応用 |
US8183040B2 (en) * | 2008-04-15 | 2012-05-22 | New York University | Methods for in vitro differentiation of Th-17+cells |
-
2011
- 2011-08-19 EP EP21160559.7A patent/EP3875474A1/en active Pending
- 2011-08-19 CN CN201810559215.5A patent/CN108822215B/zh active Active
- 2011-08-19 EP EP11818438.1A patent/EP2607380B1/en active Active
- 2011-08-19 EP EP18188839.7A patent/EP3424946B1/en active Active
- 2011-08-19 WO PCT/KR2011/006158 patent/WO2012023838A2/ko active Application Filing
- 2011-08-19 JP JP2013525818A patent/JP5911869B2/ja active Active
- 2011-08-19 US US13/818,062 patent/US9546221B2/en active Active
- 2011-08-19 CN CN201180050943.XA patent/CN103314012B/zh active Active
Patent Citations (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN101511873A (zh) * | 2006-08-31 | 2009-08-19 | 为人技术株式会社 | 用于抑制神经递质分泌的融合多肽和递送该融合多肽的方法 |
Non-Patent Citations (4)
Title |
---|
JETTEN ET.AL: "Retinoid-rlated orphan receptors(RORs):critical roles in development, immunity, circadian rhythm, and cellular metabolism", 《NUCLEAR RECEPTOR SIGNALING》 * |
吴立旋: "转录因子T-bet、GATA-3、RORgammat及FOXP3在肝癌患者外周血中表达情况的研究", 《汕头大学医学院2006级硕士学位论文》 * |
招倩倩: "PTD-△miniDBD融合蛋白体外功能的研究以及PTD-Foxp3融合蛋白对小鼠T淋巴瘤细胞的增殖及细胞凋亡的影响", 《江苏大学硕士学位论文》 * |
胡斯明 等: "哮喘小鼠肺组织中转录因子RORyt的表达与气道炎症的关系", 《中国免疫学杂志》 * |
Cited By (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN104530241A (zh) * | 2014-12-15 | 2015-04-22 | 武汉市畜牧兽医科学研究所 | 一种表达穿膜肽融合蛋白的基因工程菌及应用 |
CN104530241B (zh) * | 2014-12-15 | 2018-05-18 | 武汉市畜牧兽医科学研究所 | 一种表达穿膜肽融合蛋白的基因工程菌及应用 |
CN114958921A (zh) * | 2022-04-18 | 2022-08-30 | 复旦大学附属中山医院 | 一种提高调节型t细胞稳定性和功能的方法 |
Also Published As
Publication number | Publication date |
---|---|
US20130231274A1 (en) | 2013-09-05 |
US9546221B2 (en) | 2017-01-17 |
EP3875474A1 (en) | 2021-09-08 |
CN103314012B (zh) | 2018-07-10 |
CN108822215B (zh) | 2022-10-14 |
CN108822215A (zh) | 2018-11-16 |
EP3424946B1 (en) | 2021-08-04 |
EP2607380A4 (en) | 2014-03-12 |
JP2013541327A (ja) | 2013-11-14 |
EP3424946A3 (en) | 2019-02-20 |
WO2012023838A3 (ko) | 2012-05-24 |
EP2607380B1 (en) | 2018-10-10 |
JP5911869B2 (ja) | 2016-04-27 |
EP3424946A2 (en) | 2019-01-09 |
WO2012023838A2 (ko) | 2012-02-23 |
EP2607380A2 (en) | 2013-06-26 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
JP2018524393A (ja) | 免疫応答を誘導するための新規方法 | |
CN103314012A (zh) | 具有转录调控域和蛋白转导域的融合蛋白以及含有其的转录因子功能抑制剂 | |
US10688132B2 (en) | Coordinating gene expression using RNA destabilizing elements | |
Lugade et al. | Nrf2 regulates chronic lung inflammation and B-cell responses to nontypeable Haemophilus influenzae | |
CA2497226A1 (en) | Pharmaceutical compositions and medical treatments comprising notch ligand proteins | |
Li et al. | Intranasal immunization with recombinant Lactococci carrying human papillomavirus E7 protein and mouse interleukin‑12 DNA induces E7‑specific antitumor effects in C57BL/6 mice | |
US20190099461A1 (en) | Rna viruses for immunovirotherapy | |
KR20220097928A (ko) | 뇌암을 치료하기 위한 조합 요법 | |
KR20210091323A (ko) | 면역조절 단백질 발현용 다유전자 구조체 및 이의 사용 방법 | |
KR20190130665A (ko) | 면역 조절 | |
JP7413629B2 (ja) | Igf-1異型体を発現させるdnaコンストラクトを用いた神経病症の治療 | |
JP2004514451A (ja) | マイコバクテリア感染に対する防御 | |
KR101525856B1 (ko) | 전사인자의 dna 결합 도메인 및 단백질 운반 도메인을 포함하는 융합단백질을 가지는 전사인자 억제제 및 이의 제조방법 | |
CN110623977A (zh) | 靶向bcma的嵌合抗原受体t细胞在自身免疫性疾病中的应用 | |
JP2023527205A (ja) | 改良されたワクチン製剤 | |
US20200289589A1 (en) | Compositions and methods for treating alzheimer's disease | |
EP2024538B1 (en) | Chlamydia polypeptide | |
US20220000976A1 (en) | Methods and compositions for treating or preventing the development of food allergies | |
JPWO2009122748A1 (ja) | 呼吸器系疾患又はアレルギー性疾患の治療剤 | |
US20240165216A1 (en) | Novel recombinant strain of mycobacterium smegmatis and use of same | |
KR20180109272A (ko) | 세포투과성 펩타이드와 ctCTLA4 펩타이드가 융합된 융합단백질을 유효성분으로 하는 염증성 호흡기 질환 예방 또는 치료용 약학 조성물 | |
JP6739106B2 (ja) | 自己免疫疾患の治療用ペプチド断片 | |
KR20190141209A (ko) | 피부 경화증의 치료를 위한 매트릭스 금속단백분해효소를 포함하는 자가 유래 세포의 전달 | |
JP2020164461A (ja) | 新規転写調節融合ポリペプチドを用いた血管新生の誘導方法 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
C06 | Publication | ||
PB01 | Publication | ||
C10 | Entry into substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
GR01 | Patent grant | ||
GR01 | Patent grant | ||
TR01 | Transfer of patent right |
Effective date of registration: 20181113 Address after: Seoul, South Kerean Patentee after: INDUSTRY-ACADEMIC COOPERATION FOUNDATION, YONSEI UNIVERSITY Address before: Seoul, Korea 150-918 Patentee before: Li Shangkui |
|
TR01 | Transfer of patent right | ||
TR01 | Transfer of patent right |
Effective date of registration: 20181212 Address after: Seoul, South Kerean Patentee after: Goodall T Cell Co., Ltd. Address before: Seoul, South Kerean Patentee before: INDUSTRY-ACADEMIC COOPERATION FOUNDATION, YONSEI UNIVERSITY |
|
TR01 | Transfer of patent right |